Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog
ANTITHROMBIN III ACTIVITY |
||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB1770 Geisinger Epic ID: 17587 | |
SPECIMEN COLLECTION |
||
Specimen type: |
Platelet-free plasma | |
Preferred collection container: |
||
Alternate Collection Container: |
Other size blue-top (3.2% sodium citrate) tubes (e.g., 1.8 mL, 4.5 mL)
|
|
Specimen required: |
1 mL aliquot plasma. | |
Special notes: |
|
|
SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Centrifuge the citrated blue-top tubes as soon as possible (within 60 minutes) at designated time and speed to obtain platelet-poor plasma (<10,000/µL). Using a plastic pipette, remove 1 mL of plasma and transfer to a plastic polypropylene aliquot tube and label with patient's name and a second patient identifier (e.g., date of birth, medical record number). Freeze upright and transport on dry ice. | |
Transport temperature: |
Frozen. | |
Specimen stability: |
Frozen: -20°C for 30 days, -70°C for 6 months. Room temperature: 8 hours. | |
Rejection criteria: |
Clotted specimen. Underfilled or overfilled tube. Stability limits exceeded. If HCT > 55%, cancel test and reorder/recollect with proper adjustment of anticoagulant. Indications of thaw in transit are sample on slant in aliquot tube or in lid of tube. These samples will be run but will receive a comment of interpret results with caution as thawing suspected. | |
TEST DETAILS |
||
Reference interval: |
80-120%. | |
Additional information: |
Anticoagulation Impact on Coagulation Tests | |
CPT code(s): |
85300 | |
Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Antithrombin level. | |
Methodology: |
Chromogenic |
|
Synonyms: |
AT3 Antithrombin 3 Antithrombin
|
|
Clinical significance: |
Antithrombin 3 (AT3) is a blood protein produced in the liver that naturally prevents clot formation. AT3 works with heparin to stop clot production mainly by inhibiting thrombin (factor IIa) and factor Xa. Low AT3 levels increase risk of blood clots in patients and decrease response to heparin therapy. AT3 levels are low during or immediately after a blood clot, in patients with kidney or liver disease, and during heparin therapy. | |
Doctoral Director(s:) |
Michelle Grant DO | |
Review Date: | 02/09/2023 |